Literature DB >> 24811358

[Inflammation and bone metabolism].

E Neumann1, U Müller-Ladner, K W Frommer.   

Abstract

A finely balanced relationship between bone resorption and bone formation is characteristic for a healthy bone metabolism. Osteoblasts are responsible for bone formation and osteoclasts for bone resorption. In general inflammatory and in particular chronic inflammatory processes influence osteoblast and osteoclast function directly or via indirect mechanisms. Bone metabolism can be influenced by the interaction of cytokines, hormones and growth factors with bone cells. A central factor involved in bone metabolism is the receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system, which is influenced by different inflammatory processes. Usually, (chronic) inflammation results in increased bone loss. The molecular mechanisms and pathophysiological pathways of bone metabolism under the influence of inflammation are summarized in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24811358     DOI: 10.1007/s00393-013-1288-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  29 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism.

Authors:  Liv Thommesen; Astrid Kamilla Stunes; Marta Monjo; Kristin Grøsvik; Margareth V Tamburstuen; Eli Kjøbli; Ståle Petter Lyngstadaas; Janne E Reseland; Unni Syversen
Journal:  J Cell Biochem       Date:  2006-10-15       Impact factor: 4.429

3.  Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Authors:  Gabriel Dischereit; Ingo H Tarner; Ulf Müller-Ladner; Uwe Lange
Journal:  Clin Rheumatol       Date:  2012-11-24       Impact factor: 2.980

4.  Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Authors:  Xiang-Hang Luo; Li-Juan Guo; Hui Xie; Ling-Qing Yuan; Xian-Ping Wu; Hou-De Zhou; Er-Yuan Liao
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

5.  High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study.

Authors:  Georg Schett; Stefan Kiechl; Siegfried Weger; Angelo Pederiva; Agnes Mayr; Manuele Petrangeli; Friedrich Oberhollenzer; Rolando Lorenzini; Kurt Redlich; Roland Axmann; Jochen Zwerina; Johann Willeit
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

6.  Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling.

Authors:  Noboru Yamaguchi; Toshio Kukita; Yin-Ji Li; Noriaki Kamio; Satoshi Fukumoto; Kazuaki Nonaka; Yuzo Ninomiya; Shigemasa Hanazawa; Yoshihisa Yamashita
Journal:  FEBS Lett       Date:  2008-01-15       Impact factor: 4.124

7.  Inflammation and repair mechanisms.

Authors:  G Schett; J Sieper
Journal:  Clin Exp Rheumatol       Date:  2009 Jul-Aug       Impact factor: 4.473

8.  Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Authors:  Robin K Dore; Stanley B Cohen; Nancy E Lane; William Palmer; William Shergy; Lifen Zhou; Huei Wang; Wayne Tsuji; Richard Newmark
Journal:  Ann Rheum Dis       Date:  2009-09-03       Impact factor: 19.103

9.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.

Authors:  Kojiro Sato; Ayako Suematsu; Kazuo Okamoto; Akira Yamaguchi; Yasuyuki Morishita; Yuho Kadono; Sakae Tanaka; Tatsuhiko Kodama; Shizuo Akira; Yoichiro Iwakura; Daniel J Cua; Hiroshi Takayanagi
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

Review 10.  The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.

Authors:  Erik Lubberts; Marije I Koenders; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2004-11-30       Impact factor: 5.156

View more
  5 in total

1.  Effects of Biliopancreatic Diversion on Bone Turnover Markers and Association with Hormonal Factors in Patients with Severe Obesity.

Authors:  Anne-Frédérique Turcotte; Thomas Grenier-Larouche; Roth-Visal Ung; David Simonyan; Anne-Marie Carreau; André C Carpentier; Fabrice Mac-Way; Laetitia Michou; André Tchernof; Laurent Biertho; Stefane Lebel; Simon Marceau; Claudia Gagnon
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 2.  [Fibroblasts as pathogenic cells in rheumatic inflammation].

Authors:  C Schönfeld; T Pap; E Neumann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

3.  Analysis of peripheral bone reconstruction after the failure of hip osteonecrosis treatment with porous tantalum rod implantation.

Authors:  Weilu Liu; Yong Hu; Zhifa Huang; Zhanjun Shi; Jun Xiao
Journal:  Int Orthop       Date:  2022-03-06       Impact factor: 3.479

4.  Correlational analysis between neutrophil granulocyte levels and osteonecrosis of the femoral head.

Authors:  Jiang Jiang; Xuqiang Liu; Baojian Lai; Dengjiong Hu; Lizhen Lai; Jiaxiang Xu; Songqing Chen; Xiaofeng Li
Journal:  BMC Musculoskelet Disord       Date:  2019-08-31       Impact factor: 2.362

5.  D-mannose attenuates bone loss in mice via Treg cell proliferation and gut microbiota-dependent anti-inflammatory effects.

Authors:  Hao Liu; Ranli Gu; Yuan Zhu; Xiaomin Lian; Siyi Wang; Xuenan Liu; Zhang Ping; Yunsong Liu; Yongsheng Zhou
Journal:  Ther Adv Chronic Dis       Date:  2020-04-17       Impact factor: 5.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.